For research use only. Not for therapeutic Use.
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].
Abelacimab (MAA868) (0.0001-1 μM) prolongs the clotting time and reduces the amount of thrombin in human plasma in a concentration-dependent manner[1].
Abelacimab (MAA868) (s.c., 3-30 mg/kg, on day 1, 85, 114) shows strong and sustained anticoagulant effects in crab-eating monkeys, significantly prolongs aPTT and has a good safety profile, with no significant toxic findings or signs of bleeding observed[1].
Abelacimab (MAA868) (i.v., 0.6 mg/kg) exhibits good anticoagulant activity to prevent carotid artery occlusion in iron chloride induced thrombosis FXI-/- C57BL/6 mice model[1].
| Catalog Number | I042188 |
| CAS Number | 2098724-83-3 |
| Purity | ≥95% |
| Reference | [1]. Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133(13):1507-1516. [2]. Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11(21):6314. |
